Wells Fargo Maintains Overweight on Autolus Therapeutics, Lowers Price Target to $5

Benzinga · 08/13 12:50
Wells Fargo analyst Yanan Zhu maintains Autolus Therapeutics (NASDAQ:AUTL) with a Overweight and lowers the price target from $6 to $5.